Compare Invesco Preferred ETF (PGX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs Revvity Inc — how do they compare? Invesco Preferred ETF trades at $10.01 (market cap $3.60B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 4.7× Invesco Preferred ETF's market cap, and Revvity Inc pays a 0.18% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Preferred ETF for 95 Days and Revvity Inc for 12 Days on average.
| PGX | RVTY | |
|---|---|---|
Market Cap | $3.60B | $16.98B |
Volume | 5,986,026 | 1,456,900 |
52-Week High | $11.61 | $157.36 |
52-Week Low | $9.97 | $82.26 |
Typical Hold Time | 95 Days | 12 Days |
Sector | — | Health |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $10.03 with a modest 0.6% daily gain, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. The stock faces fundamental data gaps with key valuation and profitability metrics unavailable. Recent corporate actions include scheduled dividend payments of $0.06 per share in July and September 2026, providing income potential for shareholders.
The outlook remains cautious due to incomplete financial data and bearish technical signals. Investment opportunity exists through dividend income, but risks include limited fundamental visibility and technical weakness. Investors require updated SEC filings and analyst coverage to assess true valuation and growth prospects.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
